Clean Biologics buys CDMO Biodextris 

Transaction enables ArchiMed-backed biopharmaceutical services group to establish North American presence and expand activities with complementary services

Biodextris provides analytical and process development, early-phase clinical manufacturing and quality control testing services for clients in the vaccine and biologics industries.

The financial terms of the deal, which has been backed by healthcare investment fund, ArchiMed, were not disclosed.

Clean Biologics said the acquisition would enable it not only to expand its activities by including Biodextris’ complementary services but also to establish a presence on the North American market as it seeks to ramp up its activities in the region.

“The cultures of the three companies in the group – Clean Cells, Naobios and now Biodextris - are very similar in terms of customer focus and personalization, making this acquisition a natural fit for the very promising expansion projects to come,” said Joseph Jammal, president and CEO of Clean Biologics.

Clean Cells was created in 2000, and offers various service for the biopharmaceutical industry, from quality control and biological safety tests to production of cell banks and GMP-grade BSL2/BSL3 virus seed stock and bacteriophages for phage therapy.

Meanwhile, its sister company, CDMO Naobios, joined the Clean Biologics group in 2019 and provides bioprocess development and GMP production for clinical batches of viral vaccines BSL2/BSL3, oncolytic viruses and viral vectors.